Helena Kullenberg1, Jenny Rossen2, Unn-Britt Johansson2,3, Maria Hagströmer2,4,5, Thomas Nyström3, Maria Kumlin2, Marie M Svedberg2. 1. Department of Health Promoting Science, Sophiahemmet University, Stockholm, Sweden. Helena.Kullenberg@shh.se. 2. Department of Health Promoting Science, Sophiahemmet University, Stockholm, Sweden. 3. Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden. 4. Division of Physiotherapy, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. 5. Academic Primary Health Care Centre, Region Stockholm, Stockholm, Sweden.
Abstract
PURPOSE: Decreasing levels of serum insulin-degrading enzyme (IDE) have been associated with an increased risk for Alzheimer´s disease (AD) in patients with type 2 diabetes mellitus (T2DM). Research on serum IDE levels in patients with T2DM is sparse and the aim of this study was to explore serum levels of IDE in patients with T2DM. METHOD: Blood serum samples were obtained from a biobank. Samples from subjects with T2DM and without metabolic disease were divided into subgroups; lifestyle treatment (n = 10), oral antidiabetic treatment (n = 17), insulin treatment (n = 20) and metabolically healthy controls (n = 18). Serum levels of IDE were analysed using specific ELISA assays. RESULTS: Serum levels of IDE were elevated in subjects with T2DM compared to metabolically healthy individuals (p = 0.033). No significant differences were detected between treatment subgroups. CONCLUSION: The present study indicates that patients with T2DM have increased serum IDE levels, compared to metabolically healthy individuals. However, for IDE to be clinically useful as a biomarker, its full function and possible use needs to be further elucidated in larger studies showing reproducible outcomes.
PURPOSE: Decreasing levels of serum insulin-degrading enzyme (IDE) have been associated with an increased risk for Alzheimer´s disease (AD) in patients with type 2 diabetes mellitus (T2DM). Research on serum IDE levels in patients with T2DM is sparse and the aim of this study was to explore serum levels of IDE in patients with T2DM. METHOD: Blood serum samples were obtained from a biobank. Samples from subjects with T2DM and without metabolic disease were divided into subgroups; lifestyle treatment (n = 10), oral antidiabetic treatment (n = 17), insulin treatment (n = 20) and metabolically healthy controls (n = 18). Serum levels of IDE were analysed using specific ELISA assays. RESULTS: Serum levels of IDE were elevated in subjects with T2DM compared to metabolically healthy individuals (p = 0.033). No significant differences were detected between treatment subgroups. CONCLUSION: The present study indicates that patients with T2DM have increased serum IDE levels, compared to metabolically healthy individuals. However, for IDE to be clinically useful as a biomarker, its full function and possible use needs to be further elucidated in larger studies showing reproducible outcomes.
Authors: Cristina M Fernández-Díaz; Beatriz Merino; José F López-Acosta; Pilar Cidad; Miguel A de la Fuente; Carmen D Lobatón; Alfredo Moreno; Malcolm A Leissring; Germán Perdomo; Irene Cózar-Castellano Journal: Am J Physiol Endocrinol Metab Date: 2019-09-03 Impact factor: 4.310
Authors: Y Sofer; Y Nash; E Osher; O Fursht; G Goldsmith; L Nahary; S Shaklai; K M Tordjman; M Serebro; E B Touati; M Yacobi Bach; Y Marcus; B Tal; J Sack; G Shefer; M Margaliot; N Landis; I Goldiner; W Abu Ahmad; N Stern; I Benhar; D Frenkel Journal: Endocrine Date: 2021-01-04 Impact factor: 3.633
Authors: Cristina M Fernández-Díaz; Luis Escobar-Curbelo; J F López-Acosta; Carmen D Lobatón; Alfredo Moreno; Julián Sanz-Ortega; Germán Perdomo; Irene Cózar-Castellano Journal: Histol Histopathol Date: 2018-05-04 Impact factor: 2.303
Authors: K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith Journal: Circulation Date: 2009-10-05 Impact factor: 29.690
Authors: Mirian A Kurauti; Sandra M Ferreira; Gabriela M Soares; Jean F Vettorazzi; Everardo M Carneiro; Antonio C Boschero; José M Costa-Júnior Journal: J Cell Physiol Date: 2018-10-28 Impact factor: 6.384